% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • chimakot chimakot Mar 14, 2013 2:46 PM Flag

    ESTABLISH-2 Results Imminent.

    This is an excerpt from the POPthink SA article just released.
    ESTABLISH-2 Results Imminent

    As noted above, Trius completed enrollment in the second Phase III study, ESTABLISH-2, on Dec. 10, 2012. We remind investors that ESTABLISH-1 completed enrollment on Sept. 15, 2011, and reported top-line data 95 days later on Dec. 19, 2011. Assuming a similar timeline, 95 days after Dec. 10, 2012, would be March 15, 2013. We suspect that compiling data from ESTABLISH-2 (118 clinical sites globally) will take an extra week compared to ESTABLISH-1 (84 clinical sites globally). We also note ESTABLISH-2 had far more sites outside the U.S., thus we are expecting data the last week of March 2013.

    We remain optimistic on the results of ESTABLISH-2, believing that tedizolid will demonstrate non-inferiority to linezolid on the primary endpoint of response rate, defined as cessation of spread and absence of fever at 48-72 hours. We outlined our bullish thesis on Trius in December 2012.

    Let's Ride!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies